FIELD: medicine, pharmacology, pharmacy.
SUBSTANCE: invention proposes the composition comprising xenon as NMDA-antagonist and alpha-2-adrenergic agonist used for treatment of tetanus or narcotics (alcohol) withdrawal syndrome, states with chronic pain syndrome. Also, invention relates to the anesthetic composition comprising xenon and alpha-2-adrenergic agonist and to a method for anesthesia. The synergistic interaction of xenon as NMDA-antagonist and alpha-2-adrenergic agonist provides reducing the dose and to maintain the prolonged effectiveness by prevention for arising the drug habitation to the claimed preparation.
EFFECT: valuable medicinal properties of composition.
9 cl, 6 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| XENON AS N-METHYL-D-ASPARTIC ACID ANTAGONIST | 2000 |
|
RU2257902C2 |
| METHOD OF TREATMENT OR PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES BY MEANS OF COMPOUNDS POSSESSING SELECTIVITY WITH RESPECT TO ALPHA-3-SUBUNIT OF BENZODIAZEPINE RECEPTOR | 2004 |
|
RU2354377C2 |
| LIGAND WITH WIDE RANGE OF SIMULTANEOUS RECEPTOR ACTIVITY, PHARMACEUTICAL COMPOSITION, METHOD OF PREPARING SAID COMPOSITION AND MEDICINAL AGENT | 2008 |
|
RU2374245C1 |
| METHOD FOR ANESTHETIC MAINTENANCE DURING RADICAL SURGERY FOR CANCER PATIENTS | 2016 |
|
RU2627289C1 |
| METHODS AND COMPOSITIONS FOR TREATING CRANIOCEREBRAL INJURY | 2016 |
|
RU2701565C1 |
| COMPOUNDS BEING ACTIVE AT A NEW SITE UPON RECEPTOR-OPERATED CALCIUM CANALS APPLIED FOR TREATING NEUROLOGICAL DISORDERS | 1996 |
|
RU2246300C2 |
| MEANS FOR OPIOID ABSTINENCE SYNDROME ARRESTING | 2017 |
|
RU2643588C1 |
| MEDICINAL AGENTS USED FOR PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISEASES | 2001 |
|
RU2258506C2 |
| COMBINATIONS OF COMPOUNDS MODULATING THE NMDA RECEPTOR | 2015 |
|
RU2721948C2 |
| CHROMONE DERIVATIVES, METHOD FOR PREPARING THEM AND THERAPEUTIC USES THEREOF | 2010 |
|
RU2545214C2 |
